Clinical data | |
---|---|
Other names | X4P-001; AMD-070 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C21H27N5 |
Molar mass | 349.482 g·mol−1 |
3D model (JSmol) | |
| |
|
Mavorixafor (X4P-001)[1] is an orally bioavailable CXCR4 antagonist.[2] Developed by X4 Pharmaceuticals, it has been tested in clinical trials for WHIM syndrome,[3] melanoma,[2] and renal cell carcinoma.[4]